FDA Reclassifies NRx Pharmaceuticals Ketamine Amendment to Minor

Key Facts

1The FDA reclassified NRx Pharmaceuticals' amendment to its Abbreviated New Drug Application (ANDA) for preservative-free ketamine from Major to Minor.

In a move reflecting regulatory progress for micro-cap biotech firms, NRx Pharmaceuticals announced it has received notification from the U.S. Food and Drug Administration (FDA). The agency has reclassified the company's amendment to its Abbreviated New Drug Application (ANDA) for preservative-free ketamine from a 'Major Amendment' to a 'Minor Amendment.' According to reports, this reclassification typically implies a shorter review timeline as it indicates the submission will not require a substantial expenditure of FDA resources.

This positive regulatory shift comes as the company advances its psychiatric treatment portfolio, with the FDA revising the GDUFA goal date to November 10, 2026. The reclassification follows the drug's previous Fast Track Designation for treating suicidal ideation in depression. This development is a critical catalyst for the firm as it navigates the final stages of the regulatory approval process for its NRX-100 candidate.

Regarding market performance, NRXP shares stood at $3.49 at the close of September 14, 2026, having traded between a day high of $3.61 and a low of $3.36. Investors are looking ahead to the November 10 deadline for further regulatory clarity. Meanwhile, broader market data showed U.S. Producer Price Index (PPI) growth at 0.4% month-over-month as of September 10, 2026, providing a stable backdrop for sector-specific developments.